Skip to main content

Table 1 Efficacy of Selpercatinib in LIBRETTO-001

From: Therapeutic strategies in RET gene rearranged non-small cell lung cancer

Prior platinum doublet (n = 105)

 

ORR (%)

68 (95% CI 58–76)

Medium DOR (months)

20.3 (95% CI 13.8–24.0)

Medium PFS (months)

18.4 (95% CI 12.9–24.9)

Treatment naïve (n = 34)

 

ORR (%)

85 (95% CI 69–95)

Medium DOR (months)

NR

PFS (months)

NR

Patients with measurable CNS metastasis (n = 11)

 

ORR (%)

91% (95% CI 59–100)

  1. Most AEs were low grade. The most common adverse events of grade 3 or higher were hypertension (in 14% of the patients), an increased alanine aminotransferase level (in 12%), an increased aspartate aminotransferase level (in 10%), hyponatremia (in 6%), and lymphopenia (in 6%). Only 2% of patients discontinued selpercatinib due to AEs
  2. NR, Not Reached; ORR, Objective Response Rates; DOR, Duration of Response; PFS, Progression-Free Survival